tetano
Editor, Senior Moderator
Eur J Gastroenterol Hepatol
. 2020 Jul 3.
doi: 10.1097/MEG.0000000000001817. Online ahead of print.
COVID-19 and Liver Injury: A Meta-Analysis
Karn Wijarnpreecha[SUP] 1 [/SUP], Patompong Ungprasert[SUP] 2 [/SUP], Panadeekarn Panjawatanan[SUP] 3 [/SUP], Denise M Harnois[SUP] 1 [/SUP], Himesh B Zaver[SUP] 4 [/SUP], Aijaz Ahmed[SUP] 5 [/SUP], Donghee Kim[SUP] 5 [/SUP]
Affiliations
Abstract
Background/aims: The number of cases with coronavirus disease 2019 (COVID-19) has exceeded seven million worldwide. However, the data describing the global prevalence of liver injury associated with COVID-19 is lacking secondary to the novelty of this ongoing pandemic. Therefore, we conducted a meta-analysis to determine the association between COVID-19 and liver injury.
Methods: A systematic literature search of indexed databases including, PubMed, Medline, and Embase databases from inception to 14 April 2020, was used to identify studies that reported data of liver chemistry in patients diagnosed with COVID 19. The overall prevalence of abnormal liver chemistry and relevant 95% confidence interval was used to estimate the pooled results studies.
Results: Sixty-four studies with 11 245 patients with COVID-19 were included. The pattern of abnormal liver enzymes was notable for higher aspartate aminotransferase (AST) than alanine aminotransferase (ALT) levels. The overall global prevalence of elevated AST, ALT, total bilirubin, gamma-glutamyltransferase (GGT), and alkaline phosphatase was 23.2, 21.2, 9.7, 15.0, and 4.0%, respectively. The prevalence of elevated AST was substantially higher among those with severe cases (45.5%) compared to non-severe cases (15.0%). Co-existing chronic liver disease presented up to 37.6% of patients with COVID-19.
Conclusion: A fourth of COVID-19 patients had elevated liver enzymes and associated with disease severity. Our study may be used as a guide for clinicians and epidemiologists to proactively identify other sources of injury and illness in patients diagnosed with COVID-19. Intensive monitoring for liver injury may be needed in cases with severe COVID-19.
. 2020 Jul 3.
doi: 10.1097/MEG.0000000000001817. Online ahead of print.
COVID-19 and Liver Injury: A Meta-Analysis
Karn Wijarnpreecha[SUP] 1 [/SUP], Patompong Ungprasert[SUP] 2 [/SUP], Panadeekarn Panjawatanan[SUP] 3 [/SUP], Denise M Harnois[SUP] 1 [/SUP], Himesh B Zaver[SUP] 4 [/SUP], Aijaz Ahmed[SUP] 5 [/SUP], Donghee Kim[SUP] 5 [/SUP]
Affiliations
- PMID: 32639420
- DOI: 10.1097/MEG.0000000000001817
Abstract
Background/aims: The number of cases with coronavirus disease 2019 (COVID-19) has exceeded seven million worldwide. However, the data describing the global prevalence of liver injury associated with COVID-19 is lacking secondary to the novelty of this ongoing pandemic. Therefore, we conducted a meta-analysis to determine the association between COVID-19 and liver injury.
Methods: A systematic literature search of indexed databases including, PubMed, Medline, and Embase databases from inception to 14 April 2020, was used to identify studies that reported data of liver chemistry in patients diagnosed with COVID 19. The overall prevalence of abnormal liver chemistry and relevant 95% confidence interval was used to estimate the pooled results studies.
Results: Sixty-four studies with 11 245 patients with COVID-19 were included. The pattern of abnormal liver enzymes was notable for higher aspartate aminotransferase (AST) than alanine aminotransferase (ALT) levels. The overall global prevalence of elevated AST, ALT, total bilirubin, gamma-glutamyltransferase (GGT), and alkaline phosphatase was 23.2, 21.2, 9.7, 15.0, and 4.0%, respectively. The prevalence of elevated AST was substantially higher among those with severe cases (45.5%) compared to non-severe cases (15.0%). Co-existing chronic liver disease presented up to 37.6% of patients with COVID-19.
Conclusion: A fourth of COVID-19 patients had elevated liver enzymes and associated with disease severity. Our study may be used as a guide for clinicians and epidemiologists to proactively identify other sources of injury and illness in patients diagnosed with COVID-19. Intensive monitoring for liver injury may be needed in cases with severe COVID-19.